Next Science Limited
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more
Next Science Limited (NXSCF) - Total Assets
Latest total assets as of June 2025: $9.46 Million USD
Based on the latest financial reports, Next Science Limited (NXSCF) holds total assets worth $9.46 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Next Science Limited - Total Assets Trend (2016–2024)
This chart illustrates how Next Science Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Next Science Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Next Science Limited's total assets of $9.46 Million consist of 65.7% current assets and 34.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.2% |
| Accounts Receivable | $3.34 Million | 36.2% |
| Inventory | $726.24K | 7.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $828.15K | 9.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Next Science Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Next Science Limited's current assets represent 65.7% of total assets in 2024, an increase from 58.0% in 2016.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2024, down from 49.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 25.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 36.2% of total assets.
Next Science Limited Competitors by Total Assets
Key competitors of Next Science Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Next Science Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Next Science Limited generates 2.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Next Science Limited is currently not profitable relative to its asset base.
Next Science Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 2.17 | 7.25 |
| Quick Ratio | 1.25 | 1.96 | 7.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.82 Million | $ 4.41 Million | $ 11.03 Million |
Next Science Limited - Advanced Valuation Insights
This section examines the relationship between Next Science Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.77 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | -48.5% |
| Total Assets | $9.21 Million |
| Market Capitalization | $5.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Next Science Limited's assets below their book value (0.58 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Next Science Limited's assets decreased by 48.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Next Science Limited (2016–2024)
The table below shows the annual total assets of Next Science Limited from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.21 Million | -48.53% |
| 2023-12-31 | $17.90 Million | -2.57% |
| 2022-12-31 | $18.37 Million | +34.35% |
| 2021-12-31 | $13.67 Million | -41.79% |
| 2020-12-31 | $23.49 Million | +3.44% |
| 2019-12-31 | $22.71 Million | -13.24% |
| 2018-12-31 | $26.18 Million | +527.76% |
| 2017-12-31 | $4.17 Million | +162.54% |
| 2016-12-31 | $1.59 Million | -- |